Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in dermatologic medical technology, will participate in the Lytham Partners Summer 2022 Investor Conference on June 21-22, 2022. This virtual event will include one-on-one meetings with management, aimed at enhancing investor engagement.

STRATA focuses on innovative treatment solutions for various skin conditions, including psoriasis and acne, through products like the XTRAC and TheraClear systems. The company’s unique business model emphasizes Direct to Consumer advertising to grow its partner dermatology clinics.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Michael E. Goodman as its Head of International Sales, a newly created position aimed at enhancing the company's global market presence. Goodman, who has nearly two decades of experience in medical laser sales, will lead strategies across Europe, Asia, and Latin America. His role involves providing insights for successful international sales expansion. STRATA develops innovative dermatologic products, including excimer lasers for treating skin conditions affecting over 31 million U.S. patients.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2022 revenue of $7.0 million, a 21% increase from Q1 2021. Gross profit was $4.1 million (59% of revenues), down from 64% YoY. The company recorded a net loss of $2.5 million, equivalent to a loss of $0.07 per share. The installed base of XTRAC devices reached 903. Strata anticipates 2022 revenues between $33 million and $35 million, reflecting an expected 10%-17% growth. The company plans to launch a new FDA-approved product in Q3 2022 and expand into new markets globally.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) plans to announce its Q1 2022 financial results on May 11, 2022, at 4:30 p.m. ET, followed by a conference call. The company specializes in innovative dermatologic treatments, including excimer lasers for conditions like psoriasis and acne. With a growing portfolio including the recently acquired TheraClear® system, STRATA targets a $5.5 billion U.S. acne care market. The conference call will also provide a corporate update, and interested parties can access it through STRATA’s website.

STRATA Skin Sciences (NASDAQ: SSKN) has become a corporate sponsor of the Global Vitiligo Foundation, which aims to enhance the quality of life for those affected by vitiligo, impacting around 70 million people globally. CEO Bob Moccia emphasized the alignment of this partnership with STRATA's mission to develop innovative treatments for dermatological conditions. The company’s XTRAC excimer laser technology is designed for treating vitiligo and other autoimmune skin diseases, contributing to increased awareness and education concerning available treatment options.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The company's webcast presentation is scheduled for 11:00 AM ET on April 4 and will be accessible via their website. Management will also hold virtual one-on-one meetings throughout the event. STRATA specializes in medical technology for dermatology, offering products like the XTRAC and Pharos excimer lasers for various skin conditions, impacting over 31 million patients in the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) announced its 2021 financial results, showing a 30% revenue increase to $30 million. The fourth quarter revenue hit $9.1 million, a 35% year-over-year growth. Global recurring revenue for 2021 rose to $22.5 million, up 29%. Despite this, they reported a net loss of $2.7 million for the year. The company entered the $5.5 billion acne treatment market via the acquisition of Theraclear. Looking ahead, STRATA expects 2022 revenue between $33 million and $35 million, indicating strong growth despite challenges.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announces that John Bagdasarian has been appointed as Vice President of Professional Relations. His role focuses on strengthening relationships in dermatology and leading the company's participation in dermatological meetings. STRATA will be present at the Annual American Academy of Dermatology Meeting from March 25-29, 2022, in Boston. The company's product portfolio includes advanced laser technologies for treating various skin conditions affecting over 31 million patients in the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) announced it will release its fourth quarter and full year 2021 financial results on March 21, 2022, followed by a conference call at 4:30 p.m. ET. The call will review financial performance and provide corporate updates. STRATA focuses on developing innovative dermatological products, including excimer lasers and treatment systems for conditions like psoriasis and acne, targeting a significant patient base in the U.S.